# A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

> **NCT02826018** · PHASE1 · TERMINATED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis B
- Chronic Hepatitis B
- Hepatitis B, Chronic
- Hepatitis B Infection
- HBV

## Interventions

- **DRUG:** ALN-HBV
- **DRUG:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT02826018
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-24
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02826018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02826018, "A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02826018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*